Is the interferon response compatible with every cell state?
The type I interferon system is presented as a general vertebrate defence available to any cell. Pluripotent stem cells are the standing exception. Work from several groups had established that mouse embryonic stem cells and human pluripotent cells respond poorly to viral and bacterial patterns and produce little transcriptional output after interferon beta treatment, and that low receptor levels account for only part of that. Those cells are nonetheless not unusually susceptible to infection, which had been attributed variously to stem-cell-specific factors, to RNA silencing, or to constitutively elevated baseline expression of a subset of interferon-stimulated genes.
All of those accounts answer how the response is absent. None answers why the system is unused. Reframing the question as compatibility rather than deficiency changes what has to be measured. Instead of asking what blocks the response, one asks what engaging it would cost the cell.
Both publications are lab-led. Eggenberger 2019 has tenOever as senior and corresponding author. tenOever 2016 is a single-author Perspective, so almost all of the primary science it discusses belongs to other groups and is attributed to them in the record, and the article is not evidence that this laboratory performed that work.
Eggenberger 2019 built a system in which the comparison is internal. Human primary foreskin fibroblasts were reprogrammed to induced pluripotent stem cells and then redifferentiated to fibroblasts, so pluripotent and differentiated states of one genetic background could be set side by side. Only the pluripotent state failed to respond to 5 prime triphosphate RNA, to interferon beta, or to influenza A virus lacking NS1, and redifferentiation restored responsiveness, which excludes clonal selection or loss of genetic material as the explanation. Mouse embryonic stem cells behaved the same way, extending the observation beyond reprogrammed cells and across species. Probing the block from the direction of the reprogramming factors, co-expression of OCT4, SOX2 or KLF4 with a constitutively active IRF7 in competent cells repressed induction of IFIT1 and ISG15, with KLF4 the most potent, and KLF4 retained its own transcriptional footprint while neutralising the IRF7 output. Because the KLF4 motif does not overlap the response element, the authors infer an indirect route through chromatin and rest that inference on published accessibility data rather than on measurements made here. They also note that this account does not explain the reduced phosphorylation of IRF3, nuclear factor kappa B and STAT1 that they observe.
The consequence side is where the study makes its case. A doxycycline-inducible truncated IRF7 lacking residues 247 to 467 bypasses the requirement for kinase activation and drives interferon-stimulated genes directly, which is the only way the authors could engage the program in these cells at all. A forty-eight hour pulse induced interferon-stimulated genes and changed morphology, and after five days of rest roughly 2,000 genes remained differentially expressed even though IRF7 and its direct targets had returned to baseline. Pluripotency was not formally lost, but NANOG and IDO1 were dysregulated, and subsequent differentiation was compromised for ectoderm and endoderm and distorted within mesoderm, with cardiomyocyte cultures beating more at day 20 alongside roughly 5,000 differentially expressed genes. The authors read that as successful but aberrant differentiation.
tenOever 2016 supplies the frame in which such an incompatibility is intelligible. The Perspective reads antiviral defence across the three domains of life as repeated reassembly of a small parts list, a sequence-specific guide joined to an effector, from bacterial antisense RNA and restriction systems through prokaryotic Argonaute, CRISPR-Cas, piRNAs and RNA interference, with chordates substituting pattern recognition receptors derived from Toll-like proteins coupled to secreted cytokines. Its own proposal, labelled an attractive hypothesis whose evolutionary cause cannot be determined, is that chordates did not merely make RNA interference redundant but could not keep it, because systemic small RNA defence in a large organism would require an RNA-dependent RNA polymerase and expressing such a polymerase in mammalian somatic cells triggers innate immunity. The supporting evidence for mutual exclusivity is correlative and includes the divergent handling of long double-stranded RNA by stem and somatic cells.
The order matters. The 2016 Perspective argues in general terms that two defence systems can be incompatible and that stem and somatic cells sit on opposite sides of that divide. Eggenberger 2019 then tests one version of incompatibility experimentally, in the direction the Perspective did not, by asking what the interferon program does to a pluripotent cell rather than what a polymerase would do to a somatic one. Eggenberger 2019 also cites the Perspective for its opening framing, so the connection is textual and not only thematic.
The line stops there within this area. No later publication in the corpus returns to pluripotency, and the framing that the two systems are incompatible is presented by the authors as a hypothesis their data support. The central manipulation is artificial, since the truncated IRF7 drives a partial program and bypasses upstream signalling entirely, dose and duration are fixed at one pulse, the work rests on a small number of clones, all differentiation is in vitro, and the authors state that whether the mesoderm bias is a property of the response or of their particular line is unresolved.
The Perspective belongs equally to small RNA biology and the limits of antiviral silencing, where its incompatibility hypothesis is the organising claim and where the laboratory's report that engineered mammalian RNA interference can negate the requirement for the interferon response, Benitez 2015 on engineered RNAi, supplies its principal supporting observation. Eggenberger 2019 depends on transcription factor selectivity for its central tool, since Schmid 2010 and Schmid 2014 established the properties of IRF7 that make a constitutively active truncation a sufficient driver of interferon-stimulated genes without interferon signalling. The idea that the interferon response carries costs beyond its antiviral benefit recurs in calibration of the response in vivo, where surviving infected airway cells and post-clearance inflammation are read the same way, and it connects onward to post-acute sequelae in the pandemic host response area.
Forcing an interferon-stimulated gene program in human induced pluripotent stem cells with a constitutively active IRF7 produces lasting transcriptional change and impaired germ layer differentiation, supporting the proposal that the canonical type I interferon system and pluripotency are difficult to hold simultaneously.
A synthesis arguing that antiviral defenses across the three domains of life reuse a small set of designs, antisense recognition joined to nuclease activity and later to transcriptional and secreted responses, and proposing that chordates lost RNA interference through incompatibility with interferon.